CA2715557A1 - Inhibitors of the chemokine receptor cxcr3 - Google Patents
Inhibitors of the chemokine receptor cxcr3 Download PDFInfo
- Publication number
- CA2715557A1 CA2715557A1 CA2715557A CA2715557A CA2715557A1 CA 2715557 A1 CA2715557 A1 CA 2715557A1 CA 2715557 A CA2715557 A CA 2715557A CA 2715557 A CA2715557 A CA 2715557A CA 2715557 A1 CA2715557 A1 CA 2715557A1
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- resin
- optionally substituted
- dmf
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 10
- 101150004010 CXCR3 gene Proteins 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 250
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 230000001404 mediated effect Effects 0.000 claims abstract description 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000009410 Chemokine receptor Human genes 0.000 claims abstract description 9
- 108050000299 Chemokine receptor Proteins 0.000 claims abstract description 9
- -1 phenylcyclopropyl Chemical group 0.000 claims description 169
- 238000000034 method Methods 0.000 claims description 158
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000001153 fluoro group Chemical group F* 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 125000004122 cyclic group Chemical group 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 150000001204 N-oxides Chemical class 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000004962 physiological condition Effects 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 550
- 229920005989 resin Polymers 0.000 description 408
- 239000011347 resin Substances 0.000 description 408
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 242
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 228
- 239000000203 mixture Substances 0.000 description 212
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 145
- 239000000243 solution Substances 0.000 description 123
- 238000000746 purification Methods 0.000 description 122
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 92
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 88
- 239000007821 HATU Substances 0.000 description 85
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 72
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 72
- 238000011282 treatment Methods 0.000 description 72
- 230000008878 coupling Effects 0.000 description 69
- 238000010168 coupling process Methods 0.000 description 69
- 238000005859 coupling reaction Methods 0.000 description 69
- 239000003643 water by type Substances 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 58
- 238000004128 high performance liquid chromatography Methods 0.000 description 54
- 238000003776 cleavage reaction Methods 0.000 description 52
- 239000000284 extract Substances 0.000 description 52
- 230000007017 scission Effects 0.000 description 52
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 51
- 239000012043 crude product Substances 0.000 description 50
- 239000000047 product Substances 0.000 description 47
- 102000019034 Chemokines Human genes 0.000 description 46
- 108010012236 Chemokines Proteins 0.000 description 46
- 229910052757 nitrogen Inorganic materials 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 239000002253 acid Substances 0.000 description 35
- 125000001072 heteroaryl group Chemical group 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000009472 formulation Methods 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 125000004433 nitrogen atom Chemical group N* 0.000 description 24
- 229910052731 fluorine Inorganic materials 0.000 description 23
- 239000011737 fluorine Substances 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 23
- 125000006413 ring segment Chemical group 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 229910052717 sulfur Inorganic materials 0.000 description 19
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 18
- 235000011150 stannous chloride Nutrition 0.000 description 18
- 125000004434 sulfur atom Chemical group 0.000 description 18
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 238000004108 freeze drying Methods 0.000 description 13
- 125000006242 amine protecting group Chemical group 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 229910008066 SnC12 Inorganic materials 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 11
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 11
- 125000000464 thioxo group Chemical group S=* 0.000 description 11
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 238000005984 hydrogenation reaction Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- BOJWTAQWPVBIPG-UHFFFAOYSA-N 4-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 BOJWTAQWPVBIPG-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 7
- 239000002262 Schiff base Substances 0.000 description 7
- 150000004753 Schiff bases Chemical class 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000534944 Thia Species 0.000 description 6
- 125000003435 aroyl group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- DTGGNTMERRTPLR-UHFFFAOYSA-N 1,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(N)CC1=CC=CC=C1 DTGGNTMERRTPLR-UHFFFAOYSA-N 0.000 description 4
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VHJKDOLGYMULOP-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1Cl VHJKDOLGYMULOP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 4
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- AYXBAIULRDEVAS-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide Chemical compound [I-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 AYXBAIULRDEVAS-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- AXORVIZLPOGIRG-UHFFFAOYSA-N β-methylphenethylamine Chemical compound NCC(C)C1=CC=CC=C1 AXORVIZLPOGIRG-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 3
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000006845 Michael addition reaction Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000964 angiostatic effect Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 230000035571 calor Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 238000005695 dehalogenation reaction Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000019256 formaldehyde Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- WWPITPSIWMXDPE-UHFFFAOYSA-N para-chloroamphetamine Chemical compound CC(N)CC1=CC=C(Cl)C=C1 WWPITPSIWMXDPE-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940117803 phenethylamine Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000036185 rubor Effects 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JMOXSQYGVIXBBZ-UHFFFAOYSA-N N,N-dimethyl-beta-alanine Chemical compound CN(C)CCC(O)=O JMOXSQYGVIXBBZ-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000005333 aroyloxy group Chemical group 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940043237 diethanolamine Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 108700003601 dimethylglycine Proteins 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000035620 dolor Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 2
- WQTKNBPCJKRYPA-OAQYLSRUSA-N n-[(1r)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-n-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C2=CC=CN=C2N=C1[C@@H](C)N(C(=O)CC=1C=CC(OC(F)(F)F)=CC=1)CC1=CC=CN=C1 WQTKNBPCJKRYPA-OAQYLSRUSA-N 0.000 description 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 2
- 229940007718 zinc hydroxide Drugs 0.000 description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical group C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- OHUMKYGINIODOY-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)piperazine Chemical compound C1CN(C)CCC1N1CCNCC1 OHUMKYGINIODOY-UHFFFAOYSA-N 0.000 description 1
- FLNQAPQQAZVRDA-UHFFFAOYSA-N 1-(2-(2-Hydroxyethoxy)ethyl)piperazine Chemical compound OCCOCCN1CCNCC1 FLNQAPQQAZVRDA-UHFFFAOYSA-N 0.000 description 1
- BMEMBBFDTYHTLH-UHFFFAOYSA-N 1-(2-methoxyethyl)piperazine Chemical compound COCCN1CCNCC1 BMEMBBFDTYHTLH-UHFFFAOYSA-N 0.000 description 1
- GKBPGHNDWVURBD-UHFFFAOYSA-N 1-(oxolan-2-ylmethyl)piperazine Chemical compound C1CNCCN1CC1CCCO1 GKBPGHNDWVURBD-UHFFFAOYSA-N 0.000 description 1
- NATRYEXANYVWAW-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)piperazine Chemical compound C=1C=CC=NC=1CN1CCNCC1 NATRYEXANYVWAW-UHFFFAOYSA-N 0.000 description 1
- UNGUQQBXDOAOQO-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)piperazine Chemical compound C=1C=CN=CC=1CN1CCNCC1 UNGUQQBXDOAOQO-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- VGEQUMWEQWWIJT-UHFFFAOYSA-N 1-[(1-methylpiperidin-4-yl)methyl]piperazine Chemical compound C1CN(C)CCC1CN1CCNCC1 VGEQUMWEQWWIJT-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- RZBOMSOHMOVUES-UHFFFAOYSA-N 2-(2-chlorophenyl)ethanamine Chemical compound NCCC1=CC=CC=C1Cl RZBOMSOHMOVUES-UHFFFAOYSA-N 0.000 description 1
- NRHVNPYOTNGECT-UHFFFAOYSA-N 2-(3-chlorophenyl)ethanamine Chemical compound NCCC1=CC=CC(Cl)=C1 NRHVNPYOTNGECT-UHFFFAOYSA-N 0.000 description 1
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 1
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- UWMOGINHVUVSBN-UHFFFAOYSA-N 3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)propanoic acid Chemical compound OC(=O)CCN1CC(F)(F)C(F)(F)C1 UWMOGINHVUVSBN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KYYHOIAAKQKYMH-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-(2,7-diazaspiro[3.5]nonan-7-yl)-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1NC(=O)C=2C=C(Cl)C=CC=2)=CC=C1N1CCC2(CNC2)CC1 KYYHOIAAKQKYMH-UHFFFAOYSA-N 0.000 description 1
- HMXBPLQWGXADLM-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-(2,8-diazaspiro[4.5]decan-8-yl)-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCC3(CNCC3)CC2)=C1 HMXBPLQWGXADLM-UHFFFAOYSA-N 0.000 description 1
- VLQXVKOYFASXMW-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-(3,9-diazaspiro[5.5]undecan-3-yl)-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCC3(CCNCC3)CC2)=C1 VLQXVKOYFASXMW-UHFFFAOYSA-N 0.000 description 1
- LFUDHESVTSJKSW-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-(1,2-diphenylethyl)benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC(CC=2C=CC=CC=2)C=2C=CC=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 LFUDHESVTSJKSW-UHFFFAOYSA-N 0.000 description 1
- RJKAGWKVSWJBST-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-(2-phenylcyclopropyl)benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC2C(C2)C=2C=CC=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 RJKAGWKVSWJBST-UHFFFAOYSA-N 0.000 description 1
- SQJJGYHENSDBDW-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-(2-phenylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(C)CNC(=O)C(C=C1NC(=O)C=2C=C(Cl)C=CC=2)=CC=C1N1CCN(CCN(C)C)CC1 SQJJGYHENSDBDW-UHFFFAOYSA-N 0.000 description 1
- AHTBAGDMSBHMMO-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-[2-(2-fluorophenyl)ethyl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)F)C=C1NC(=O)C1=CC=CC(Cl)=C1 AHTBAGDMSBHMMO-UHFFFAOYSA-N 0.000 description 1
- ZMHJGVXQFORIKI-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-[2-(4-fluorophenyl)ethyl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(F)=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 ZMHJGVXQFORIKI-UHFFFAOYSA-N 0.000 description 1
- UKTRKSOLLCVYON-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-n-methyl-n-(2-phenylethyl)benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)N(C)CCC=2C=CC=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 UKTRKSOLLCVYON-UHFFFAOYSA-N 0.000 description 1
- JFPANUSIIFWFSG-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[1-(4-chlorophenyl)propan-2-yl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(N2CCN(CCN(C)C)CC2)C(NC(=O)C=2C=C(Cl)C=CC=2)=CC=1C(=O)NC(C)CC1=CC=C(Cl)C=C1 JFPANUSIIFWFSG-UHFFFAOYSA-N 0.000 description 1
- TYMHEALJEYEDDQ-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-(2-methyl-2,7-diazaspiro[3.5]nonan-7-yl)benzamide Chemical compound C1N(C)CC21CCN(C=1C(=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)NC(=O)C=1C=C(Cl)C=CC=1)CC2 TYMHEALJEYEDDQ-UHFFFAOYSA-N 0.000 description 1
- NOXUXZOFJZEZEB-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-(2-methyl-2,8-diazaspiro[4.5]decan-8-yl)benzamide Chemical compound C1N(C)CCC21CCN(C=1C(=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)NC(=O)C=1C=C(Cl)C=CC=1)CC2 NOXUXZOFJZEZEB-UHFFFAOYSA-N 0.000 description 1
- UYNRUUDFNOALEE-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-(3,3-dimethyl-9-aza-3-azoniaspiro[5.5]undecan-9-yl)benzamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1C[N+](C)(C)CCC11CCN(C=2C(=CC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)NC(=O)C=2C=C(Cl)C=CC=2)CC1 UYNRUUDFNOALEE-UHFFFAOYSA-N 0.000 description 1
- RLWKNHICPQLFSY-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-(4-ethylpiperazin-1-yl)benzamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 RLWKNHICPQLFSY-UHFFFAOYSA-N 0.000 description 1
- HHTVDNHWHXKURN-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)benzamide Chemical compound C1CN(C)CCC21CCN(C=1C(=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)NC(=O)C=1C=C(Cl)C=CC=1)CC2 HHTVDNHWHXKURN-UHFFFAOYSA-N 0.000 description 1
- REZRGVCSIGDUCQ-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]benzamide Chemical compound C1CN(C)CCC1N1CCN(C=2C(=CC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)NC(=O)C=2C=C(Cl)C=CC=2)CC1 REZRGVCSIGDUCQ-UHFFFAOYSA-N 0.000 description 1
- NSUSVXPHMIEKPJ-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(2-hydroxyethyl)piperazin-1-yl]benzamide Chemical compound C1CN(CCO)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 NSUSVXPHMIEKPJ-UHFFFAOYSA-N 0.000 description 1
- KKPGZOBSPZNVBF-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(2-methoxyethyl)piperazin-1-yl]benzamide Chemical compound C1CN(CCOC)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 KKPGZOBSPZNVBF-UHFFFAOYSA-N 0.000 description 1
- IXVYVIYNBZMHEE-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCN(CCN3CCOCC3)CC2)=C1 IXVYVIYNBZMHEE-UHFFFAOYSA-N 0.000 description 1
- ILPMHPFGYLBUDS-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(3-pyrrolidin-1-ylpropanoyl)piperazin-1-yl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1NC(=O)C=2C=C(Cl)C=CC=2)=CC=C1N1CCN(C(=O)CCN2CCCC2)CC1 ILPMHPFGYLBUDS-UHFFFAOYSA-N 0.000 description 1
- DYHQCRRAHMUSOR-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(oxolan-2-ylmethyl)piperazin-1-yl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1NC(=O)C=2C=C(Cl)C=CC=2)=CC=C1N1CCN(CC2OCCC2)CC1 DYHQCRRAHMUSOR-UHFFFAOYSA-N 0.000 description 1
- BIYUOQNAISWMFN-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(pyridin-2-ylmethyl)piperazin-1-yl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCN(CC=3N=CC=CC=3)CC2)=C1 BIYUOQNAISWMFN-UHFFFAOYSA-N 0.000 description 1
- VXLIDVAQFWYCJR-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCN(CC=3C=NC=CC=3)CC2)=C1 VXLIDVAQFWYCJR-UHFFFAOYSA-N 0.000 description 1
- ZGPWNXFUMKHZOU-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[(1-methylpiperidin-4-yl)methyl]piperazin-1-yl]benzamide Chemical compound C1CN(C)CCC1CN1CCN(C=2C(=CC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)NC(=O)C=2C=C(Cl)C=CC=2)CC1 ZGPWNXFUMKHZOU-UHFFFAOYSA-N 0.000 description 1
- WGKFSOYOYKZLMO-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCOCCO)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 WGKFSOYOYKZLMO-UHFFFAOYSA-N 0.000 description 1
- MCOZABQXXQHKAE-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[2-(dimethylamino)-2-oxoethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CC(=O)N(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 MCOZABQXXQHKAE-UHFFFAOYSA-N 0.000 description 1
- QWVJFAKCXXEMDZ-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[2-(dimethylamino)acetyl]piperazin-1-yl]benzamide Chemical compound C1CN(C(=O)CN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 QWVJFAKCXXEMDZ-UHFFFAOYSA-N 0.000 description 1
- YFIJFCUKIQDTIY-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 YFIJFCUKIQDTIY-UHFFFAOYSA-N 0.000 description 1
- RYMDIMPMADQJSU-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperidin-1-yl]benzamide Chemical compound C1CC(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 RYMDIMPMADQJSU-UHFFFAOYSA-N 0.000 description 1
- VRLPDPVNHGDIPL-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)propanoyl]piperazin-1-yl]benzamide Chemical compound C1C(F)(F)C(F)(F)CN1CCC(=O)N1CCN(C=2C(=CC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)NC(=O)C=2C=C(Cl)C=CC=2)CC1 VRLPDPVNHGDIPL-UHFFFAOYSA-N 0.000 description 1
- GXUKPGVWZNLPAI-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[3-(diethylamino)propanoyl]piperazin-1-yl]benzamide Chemical compound C1CN(C(=O)CCN(CC)CC)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 GXUKPGVWZNLPAI-UHFFFAOYSA-N 0.000 description 1
- UNMYDMGJCLVXRL-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[3-(dimethylamino)propanoyl]piperazin-1-yl]benzamide Chemical compound C1CN(C(=O)CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 UNMYDMGJCLVXRL-UHFFFAOYSA-N 0.000 description 1
- RXWDRKWOKQKRQX-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 RXWDRKWOKQKRQX-UHFFFAOYSA-N 0.000 description 1
- GFXRDOFRFRNQSK-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]-4-[4-[3-(methylamino)propanoyl]piperazin-1-yl]benzamide Chemical compound C1CN(C(=O)CCNC)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 GFXRDOFRFRNQSK-UHFFFAOYSA-N 0.000 description 1
- LWMPMMGZPIXZFD-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2,6-dichlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2Cl)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 LWMPMMGZPIXZFD-UHFFFAOYSA-N 0.000 description 1
- AIRYGLYMGRNXLK-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(2-chlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 AIRYGLYMGRNXLK-UHFFFAOYSA-N 0.000 description 1
- QESNSHRSQCTTQA-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(3-chlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=C(Cl)C=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 QESNSHRSQCTTQA-UHFFFAOYSA-N 0.000 description 1
- VSCPHUYJYNPNLF-UHFFFAOYSA-N 3-[(3-chlorobenzoyl)amino]-n-[2-(4-chlorophenyl)ethyl]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 VSCPHUYJYNPNLF-UHFFFAOYSA-N 0.000 description 1
- GZMWWZBSMGACGA-UHFFFAOYSA-N 3-[[5-[2-(2,4-dichlorophenyl)ethylcarbamoyl]-2-[4-[3-(dimethylamino)propanoyl]piperazin-1-yl]phenyl]carbamoyl]benzoic acid Chemical compound C1CN(C(=O)CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(C(O)=O)=C1 GZMWWZBSMGACGA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- BRSKDXVJFXXUKX-UHFFFAOYSA-N 3-pyrrolidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCC1 BRSKDXVJFXXUKX-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- SAJZEJMFAWZNCQ-UHFFFAOYSA-N 4-(2-piperazin-1-ylethyl)morpholine Chemical compound C1CNCCN1CCN1CCOCC1 SAJZEJMFAWZNCQ-UHFFFAOYSA-N 0.000 description 1
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- NHVQTENSKKEUMQ-UHFFFAOYSA-N 4-[2-[(3-chlorobenzoyl)amino]-4-[2-(2,4-dichlorophenyl)ethylcarbamoyl]phenyl]-n-ethylpiperazine-1-carboxamide Chemical compound C1CN(C(=O)NCC)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 NHVQTENSKKEUMQ-UHFFFAOYSA-N 0.000 description 1
- MCTDQCBPKJYSHN-UHFFFAOYSA-N 4-[4-(2-aminoethyl)piperazin-1-yl]-3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1CN(CCN)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 MCTDQCBPKJYSHN-UHFFFAOYSA-N 0.000 description 1
- KQZWZCXQELQMSI-UHFFFAOYSA-N 4-[4-(3-aminopropanoyl)piperazin-1-yl]-3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1CN(C(=O)CCN)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=CC(Cl)=C1 KQZWZCXQELQMSI-UHFFFAOYSA-N 0.000 description 1
- HGILWWCUMUZSIH-UHFFFAOYSA-N 4-[4-[3-(aziridin-1-yl)propanoyl]piperazin-1-yl]-3-[(3-chlorobenzoyl)amino]-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)N2CCN(CC2)C(=O)CCN2CC2)=C1 HGILWWCUMUZSIH-UHFFFAOYSA-N 0.000 description 1
- OTNIZMHCFIINQW-UHFFFAOYSA-N 4-[[5-[2-(2,4-dichlorophenyl)ethylcarbamoyl]-2-[4-[3-(dimethylamino)propanoyl]piperazin-1-yl]phenyl]carbamoyl]benzoic acid Chemical compound C1CN(C(=O)CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1NC(=O)C1=CC=C(C(O)=O)C=C1 OTNIZMHCFIINQW-UHFFFAOYSA-N 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- MAPLZJAGYJXMIM-UHFFFAOYSA-N 5-(4-chlorophenyl)pentan-2-amine Chemical compound CC(N)CCCC1=CC=C(Cl)C=C1 MAPLZJAGYJXMIM-UHFFFAOYSA-N 0.000 description 1
- HEOQXHNKRXRCTO-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene Chemical class C1CCCCC2=CC=CC=C21 HEOQXHNKRXRCTO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- LZJGQIVWUKFTRD-UHFFFAOYSA-N 7-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1NC=C2 LZJGQIVWUKFTRD-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000058084 Aegle marmelos Species 0.000 description 1
- 235000003930 Aegle marmelos Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101710198774 Envelope protein US9 Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- MTFCXMJOGMHYAE-UHFFFAOYSA-N Ethyl piperazinoacetate Chemical compound CCOC(=O)CN1CCNCC1 MTFCXMJOGMHYAE-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100441533 Mus musculus Cxcl9 gene Proteins 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000006307 alkoxy benzyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 230000010252 chemokine signaling pathway Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 101150115039 mig gene Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- JJEMPZXXGBIJIX-UHFFFAOYSA-N n,n-dimethyl-2-piperazin-1-ylacetamide Chemical compound CN(C)C(=O)CN1CCNCC1 JJEMPZXXGBIJIX-UHFFFAOYSA-N 0.000 description 1
- LGDNSGSJKBIVFG-UHFFFAOYSA-N n,n-dimethyl-2-piperazin-1-ylethanamine Chemical compound CN(C)CCN1CCNCC1 LGDNSGSJKBIVFG-UHFFFAOYSA-N 0.000 description 1
- RSFAUZNVDWGQBZ-UHFFFAOYSA-N n,n-dimethyl-2-piperidin-4-ylethanamine Chemical compound CN(C)CCC1CCNCC1 RSFAUZNVDWGQBZ-UHFFFAOYSA-N 0.000 description 1
- PBYWPPVOKKHKHA-UHFFFAOYSA-N n-[2-(4-bromophenyl)ethyl]-3-[(3-chlorobenzoyl)amino]-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]benzamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Br)=CC=2)C=C1NC(=O)C1=CC=CC(Cl)=C1 PBYWPPVOKKHKHA-UHFFFAOYSA-N 0.000 description 1
- OSTGMXIHSCMYOX-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(1,2-diphenylethylcarbamoyl)phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC(CC=2C=CC=CC=2)C=2C=CC=CC=2)C=C1NC(=O)C1=CC=CS1 OSTGMXIHSCMYOX-UHFFFAOYSA-N 0.000 description 1
- OQZJFGFGIDSTFT-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(1,2-diphenylethylcarbamoyl)phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC(CC=2C=CC=CC=2)C=2C=CC=CC=2)C=C1NC(=O)C1=CSC=C1 OQZJFGFGIDSTFT-UHFFFAOYSA-N 0.000 description 1
- DWSLAUYODAEDRY-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(2-phenylpropylcarbamoyl)phenyl]thiophene-2-carboxamide Chemical compound C=1C=CC=CC=1C(C)CNC(=O)C(C=C1NC(=O)C=2SC=CC=2)=CC=C1N1CCN(CCN(C)C)CC1 DWSLAUYODAEDRY-UHFFFAOYSA-N 0.000 description 1
- ACWZIJCJBWAYEN-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(2-phenylpropylcarbamoyl)phenyl]thiophene-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)CNC(=O)C(C=C1NC(=O)C2=CSC=C2)=CC=C1N1CCN(CCN(C)C)CC1 ACWZIJCJBWAYEN-UHFFFAOYSA-N 0.000 description 1
- PGNHCNNUXPLNNH-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[(2-phenylcyclopropyl)carbamoyl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC2C(C2)C=2C=CC=CC=2)C=C1NC(=O)C1=CC=CS1 PGNHCNNUXPLNNH-UHFFFAOYSA-N 0.000 description 1
- AQYKMPWZWGIMAZ-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[(2-phenylcyclopropyl)carbamoyl]phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NC2C(C2)C=2C=CC=CC=2)C=C1NC(=O)C1=CSC=C1 AQYKMPWZWGIMAZ-UHFFFAOYSA-N 0.000 description 1
- IKWOWLFTDYHWHG-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[2-(2-fluorophenyl)ethylcarbamoyl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)F)C=C1NC(=O)C1=CC=CS1 IKWOWLFTDYHWHG-UHFFFAOYSA-N 0.000 description 1
- QCCPIYWRLNQVBM-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[2-(2-fluorophenyl)ethylcarbamoyl]phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)F)C=C1NC(=O)C1=CSC=C1 QCCPIYWRLNQVBM-UHFFFAOYSA-N 0.000 description 1
- UTRGMNQFNKUXSJ-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[2-(4-fluorophenyl)ethylcarbamoyl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(F)=CC=2)C=C1NC(=O)C1=CC=CS1 UTRGMNQFNKUXSJ-UHFFFAOYSA-N 0.000 description 1
- IRVCVJZXKLLRFX-UHFFFAOYSA-N n-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-[2-(4-fluorophenyl)ethylcarbamoyl]phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(F)=CC=2)C=C1NC(=O)C1=CSC=C1 IRVCVJZXKLLRFX-UHFFFAOYSA-N 0.000 description 1
- SRAWVJVPKDOSJQ-UHFFFAOYSA-N n-[5-[1-(4-chlorophenyl)propan-2-ylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C=1C=C(N2CCN(CCN(C)C)CC2)C(NC(=O)C=2SC=CC=2)=CC=1C(=O)NC(C)CC1=CC=C(Cl)C=C1 SRAWVJVPKDOSJQ-UHFFFAOYSA-N 0.000 description 1
- CIYWDWCBPDATBX-UHFFFAOYSA-N n-[5-[1-(4-chlorophenyl)propan-2-ylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-3-carboxamide Chemical compound C=1C=C(N2CCN(CCN(C)C)CC2)C(NC(=O)C2=CSC=C2)=CC=1C(=O)NC(C)CC1=CC=C(Cl)C=C1 CIYWDWCBPDATBX-UHFFFAOYSA-N 0.000 description 1
- FKPPGRMCWMAOJR-UHFFFAOYSA-N n-[5-[2-(2,6-dichlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2Cl)Cl)C=C1NC(=O)C1=CC=CS1 FKPPGRMCWMAOJR-UHFFFAOYSA-N 0.000 description 1
- RWAMANWXXVBRRW-UHFFFAOYSA-N n-[5-[2-(2,6-dichlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2Cl)Cl)C=C1NC(=O)C1=CSC=C1 RWAMANWXXVBRRW-UHFFFAOYSA-N 0.000 description 1
- PCFDNUDINWGIGR-UHFFFAOYSA-N n-[5-[2-(2-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)Cl)C=C1NC(=O)C1=CC=NC=C1 PCFDNUDINWGIGR-UHFFFAOYSA-N 0.000 description 1
- GTDKMRZRFLLBPW-UHFFFAOYSA-N n-[5-[2-(2-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C(=CC=CC=2)Cl)C=C1NC(=O)C1=CC=CS1 GTDKMRZRFLLBPW-UHFFFAOYSA-N 0.000 description 1
- AWJHQGANCDZIHT-UHFFFAOYSA-N n-[5-[2-(3-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=C(Cl)C=CC=2)C=C1NC(=O)C1=CC=NC=C1 AWJHQGANCDZIHT-UHFFFAOYSA-N 0.000 description 1
- SUWLORQJKLQXBI-UHFFFAOYSA-N n-[5-[2-(3-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=C(Cl)C=CC=2)C=C1NC(=O)C1=CC=CS1 SUWLORQJKLQXBI-UHFFFAOYSA-N 0.000 description 1
- CJFUUTYAHWKCPP-UHFFFAOYSA-N n-[5-[2-(4-bromophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Br)=CC=2)C=C1NC(=O)C1=CC=CS1 CJFUUTYAHWKCPP-UHFFFAOYSA-N 0.000 description 1
- NFONQDJFSBUFME-UHFFFAOYSA-N n-[5-[2-(4-bromophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-3-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Br)=CC=2)C=C1NC(=O)C1=CSC=C1 NFONQDJFSBUFME-UHFFFAOYSA-N 0.000 description 1
- DYCNNUGBJNJRBG-UHFFFAOYSA-N n-[5-[2-(4-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1NC(=O)C1=CC=NC=C1 DYCNNUGBJNJRBG-UHFFFAOYSA-N 0.000 description 1
- NTMNDORPJDDGQR-UHFFFAOYSA-N n-[5-[2-(4-chlorophenyl)ethylcarbamoyl]-2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]thiophene-2-carboxamide Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1NC(=O)C1=CC=CS1 NTMNDORPJDDGQR-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- LQQPFNQTRZLLOQ-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C(=O)OC(C)(C)C)CC21CCNCC2 LQQPFNQTRZLLOQ-UHFFFAOYSA-N 0.000 description 1
- QBFUESKHODOMGJ-UHFFFAOYSA-N tert-butyl 2,8-diazaspiro[4.5]decane-1-carboxylate Chemical compound CC(C)(C)OC(=O)C1NCCC11CCNCC1 QBFUESKHODOMGJ-UHFFFAOYSA-N 0.000 description 1
- RACLNPISQWQPPW-UHFFFAOYSA-N tert-butyl 3,9-diazaspiro[5.5]undecane-5-carboxylate Chemical compound CC(C)(C)OC(=O)C1CNCCC11CCNCC1 RACLNPISQWQPPW-UHFFFAOYSA-N 0.000 description 1
- QSYTWBKZNNEKPN-UHFFFAOYSA-N tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCN)CC1 QSYTWBKZNNEKPN-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2973808P | 2008-02-19 | 2008-02-19 | |
| US61/029,738 | 2008-02-19 | ||
| PCT/US2009/034340 WO2009105435A1 (en) | 2008-02-19 | 2009-02-18 | Inhibitors of the chemokine receptor cxcr3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2715557A1 true CA2715557A1 (en) | 2009-08-27 |
Family
ID=40527535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2715557A Abandoned CA2715557A1 (en) | 2008-02-19 | 2009-02-18 | Inhibitors of the chemokine receptor cxcr3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8268828B2 (https=) |
| EP (1) | EP2262784B1 (https=) |
| JP (1) | JP2011512412A (https=) |
| KR (1) | KR20100123835A (https=) |
| CN (1) | CN102007108A (https=) |
| AR (1) | AR070430A1 (https=) |
| AU (1) | AU2009215643A1 (https=) |
| BR (1) | BRPI0908815A2 (https=) |
| CA (1) | CA2715557A1 (https=) |
| CL (1) | CL2009000368A1 (https=) |
| CO (1) | CO6241113A2 (https=) |
| CR (1) | CR11604A (https=) |
| DO (1) | DOP2010000254A (https=) |
| EC (1) | ECSP10010409A (https=) |
| IL (1) | IL207597A0 (https=) |
| MA (1) | MA32191B1 (https=) |
| MX (1) | MX2010008397A (https=) |
| NI (1) | NI201000132A (https=) |
| NZ (1) | NZ587380A (https=) |
| PE (1) | PE20091576A1 (https=) |
| RU (1) | RU2010138577A (https=) |
| SV (1) | SV2010003648A (https=) |
| TW (1) | TW200948791A (https=) |
| WO (1) | WO2009105435A1 (https=) |
| ZA (1) | ZA201005314B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| WO2010126811A1 (en) | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
| WO2011084985A1 (en) * | 2010-01-07 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
| KR101251788B1 (ko) | 2010-12-06 | 2013-04-08 | 기아자동차주식회사 | 차량 연비 정보 단말표시 시스템 및 그 방법 |
| WO2013012848A1 (en) * | 2011-07-18 | 2013-01-24 | Merck Patent Gmbh | Benzamides |
| EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| WO2013106409A1 (en) | 2012-01-10 | 2013-07-18 | Merck Patent Gmbh | Benzamide derivatives as modulators of the follicle stimulating hormone |
| AU2013216354B2 (en) | 2012-02-02 | 2017-08-31 | Idorsia Pharmaceuticals Ltd | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives |
| EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
| JP6330040B2 (ja) | 2013-07-22 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体 |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| BR112017004612A2 (pt) * | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| PL3245203T3 (pl) | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| JP7142675B2 (ja) * | 2017-03-26 | 2022-09-27 | 武田薬品工業株式会社 | Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド |
| CN115974766B (zh) * | 2023-01-04 | 2025-05-16 | 中国药科大学 | N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用 |
| CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719660A (en) | 1969-06-13 | 1973-03-06 | Takeda Chemical Industries Ltd | 2-furfurylthioinosine-5'-phosphate compounds |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| JP2005530813A (ja) | 2002-06-03 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | イミダゾリウムｃｘｃｒ３阻害剤 |
| US6734659B1 (en) | 2002-06-13 | 2004-05-11 | Mykrolis Corporation | Electronic interface for use with dual electrode capacitance diaphragm gauges |
| PE20061164A1 (es) | 2005-02-16 | 2006-10-27 | Schering Corp | Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 |
| JP2008530218A (ja) | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、ピリジルおよびフェニルで置換されたピペラジン−ピペリジン |
| MX2007010067A (es) * | 2005-02-16 | 2007-12-07 | Schering Corp | Compuestos heterociclicos novedosos sustituidos con piridina o fenilo con actividad antagonista de cxcr3. |
| WO2007002742A1 (en) | 2005-06-28 | 2007-01-04 | Pharmacopeia, Inc. | Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders |
| CA2625762A1 (en) | 2005-10-11 | 2007-04-26 | Schering Corporation | Substituted heterocyclic compounds with cxcr3 antagonist activity |
| US20090143413A1 (en) | 2005-11-29 | 2009-06-04 | Adams Alan D | Thiazole Derivatives as CXCR3 Receptor Modulators |
| CN101460482B (zh) | 2006-03-21 | 2013-03-27 | 默沙东公司 | 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物 |
| MX2009000577A (es) | 2006-07-14 | 2009-03-09 | Schering Corp | Compuestos de piperazina sustituida heterociclica con actividad antagonista de cxcr3. |
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
-
2009
- 2009-02-17 PE PE2009000232A patent/PE20091576A1/es not_active Application Discontinuation
- 2009-02-18 EP EP09711984.6A patent/EP2262784B1/en active Active
- 2009-02-18 MX MX2010008397A patent/MX2010008397A/es not_active Application Discontinuation
- 2009-02-18 RU RU2010138577/04A patent/RU2010138577A/ru not_active Application Discontinuation
- 2009-02-18 AU AU2009215643A patent/AU2009215643A1/en not_active Abandoned
- 2009-02-18 CL CL2009000368A patent/CL2009000368A1/es unknown
- 2009-02-18 NZ NZ587380A patent/NZ587380A/en not_active IP Right Cessation
- 2009-02-18 BR BRPI0908815A patent/BRPI0908815A2/pt not_active IP Right Cessation
- 2009-02-18 KR KR1020107018467A patent/KR20100123835A/ko not_active Withdrawn
- 2009-02-18 CA CA2715557A patent/CA2715557A1/en not_active Abandoned
- 2009-02-18 CN CN2009801138321A patent/CN102007108A/zh active Pending
- 2009-02-18 JP JP2010547712A patent/JP2011512412A/ja active Pending
- 2009-02-18 AR ARP090100561A patent/AR070430A1/es not_active Application Discontinuation
- 2009-02-18 WO PCT/US2009/034340 patent/WO2009105435A1/en not_active Ceased
- 2009-02-19 TW TW098105199A patent/TW200948791A/zh unknown
-
2010
- 2010-07-26 ZA ZA2010/05314A patent/ZA201005314B/en unknown
- 2010-07-28 CR CR11604A patent/CR11604A/es not_active Application Discontinuation
- 2010-07-29 NI NI201000132A patent/NI201000132A/es unknown
- 2010-08-06 US US12/852,076 patent/US8268828B2/en active Active
- 2010-08-12 IL IL207597A patent/IL207597A0/en unknown
- 2010-08-18 EC EC2010010409A patent/ECSP10010409A/es unknown
- 2010-08-18 DO DO2010000254A patent/DOP2010000254A/es unknown
- 2010-08-18 SV SV2010003648A patent/SV2010003648A/es not_active Application Discontinuation
- 2010-08-19 CO CO10102315A patent/CO6241113A2/es not_active Application Discontinuation
- 2010-09-13 MA MA33173A patent/MA32191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009215643A1 (en) | 2009-08-27 |
| WO2009105435A1 (en) | 2009-08-27 |
| BRPI0908815A2 (pt) | 2019-09-24 |
| ZA201005314B (en) | 2011-03-30 |
| TW200948791A (en) | 2009-12-01 |
| EP2262784A1 (en) | 2010-12-22 |
| NI201000132A (es) | 2011-03-16 |
| CO6241113A2 (es) | 2011-01-20 |
| AR070430A1 (es) | 2010-04-07 |
| EP2262784B1 (en) | 2014-04-16 |
| KR20100123835A (ko) | 2010-11-25 |
| IL207597A0 (en) | 2010-12-30 |
| NZ587380A (en) | 2011-09-30 |
| MX2010008397A (es) | 2010-08-23 |
| CN102007108A (zh) | 2011-04-06 |
| MA32191B1 (fr) | 2011-04-01 |
| US20100305088A1 (en) | 2010-12-02 |
| DOP2010000254A (es) | 2010-08-31 |
| US8268828B2 (en) | 2012-09-18 |
| CR11604A (es) | 2010-10-05 |
| JP2011512412A (ja) | 2011-04-21 |
| RU2010138577A (ru) | 2012-03-27 |
| PE20091576A1 (es) | 2009-11-05 |
| ECSP10010409A (es) | 2010-09-30 |
| CL2009000368A1 (es) | 2009-06-26 |
| SV2010003648A (es) | 2011-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8268828B2 (en) | Inhibitors of the chemokine receptor CxCR3 | |
| EP1051397B1 (en) | Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound | |
| EP1212269B1 (en) | Methods for preparing n- (aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds | |
| WO2007063385A2 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
| US8178535B2 (en) | Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments | |
| JP2023548165A (ja) | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法 | |
| AU2008329072A1 (en) | Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10 | |
| JP2010531364A (ja) | ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体 | |
| JP2023548161A (ja) | メラノコルチン受容体アゴニスト化合物の結晶形ｉｖおよびその製造方法 | |
| CN113402499B (zh) | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 | |
| JP2024501828A (ja) | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法 | |
| JP2025161919A (ja) | メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法 | |
| JP2025161920A (ja) | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法 | |
| DE60216128T2 (de) | Thieno[2,3-D]Pyrimidine mit kombinierter LH und FSH agonistischen Wirkung | |
| JP2024502281A (ja) | メラノコルチン－４受容体の選択的アゴニストとしての使用 | |
| JP5673676B2 (ja) | イミダゾ［１，２−ａ］ピリジン誘導体 | |
| CN110590592A (zh) | 非肽bdnf神经营养蛋白模拟物 | |
| CN116396284A (zh) | 苯并七元氮氧杂环吲哚-2-甲酰胺衍生物及其制备方法和用途 | |
| GB2290786A (en) | Quinoline derivatives | |
| CN109810058B (zh) | 紫金龙素类衍生物及其药物组合物、制备方法和用途 | |
| JP2003522197A (ja) | Ａ８２８４６グリコペプチドアナログの選択的ｎ−アシル化 | |
| CN120865094A (zh) | 一氢吲唑类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130821 |